Haematology/Oncology Transplant Follow-Up Center - ATMA
Hematopoietic stem cell transplantation (HSCT) is currently the only treatment approach able to cure a number of cancerous diseases and other disorders in children such as leukaemia, lymphomas, haemoglobinopathies, myelodysplastic syndromes, malignant solid tumours, aplastic anaemia, genetic immunodeficiency, metabolic and autoimmune diseases.
Every patient that receives transplantation is at high risk of infection because the immune system is suppressed.
ATMA – Advanced Treatment through a Multidisciplinary Approach (MITA - Modulo Interdisciplinare di Terapie Avanzate) is a sub-intensive unit with 10 beds, 6 of which are brand new and feature modern comforts. It was built to receive children who are at high risk of infection in positive pressure rooms (bacteria/airborne microorganisms are kept out).
A low-bacteria environment is ensured by a sophisticated air purifying system that uses filters to render the room virtually free of microorganisms. The rooms are maintained in sterile safety conditions by sterilising everything that enters: medication, equipment, food, and games.
Children admitted to ATMA are cared for by specialised oncologists and haematologists from the department, 24 hours a day.
We provide a large number of transplant services and perform over 100 hematopoietic stem cell transplants each year, divided into the following sub-types:
· Autologous transplants
· Allogeneic transplants: from an HLA-matched related donor, from HLA-haploidentical (half-matched) related donor, from an unrelated donor (on national and international donor lists), or from umbilical cord blood.
Areas of Excellence
· Haploidentical transplant using a new approach for the depletion of lymphocytes carrying alpha/beta chain receptors.
· Adoptive cell transfer
· The use of mesenchymal stem cells to promote the growth and haematopoiesis in the treatment of graft-versus-host disease (GvHD)
· The use of new medicines to treat chronic GvHD.
· The use of extracorporeal photochemotherapy (photodynamic therapy PDT) in the treatment of GvHD.
· The role of natural killer cell reactivity in hematopoietic stem cell transplantation from HLA half-matched related donors.
· The use of adoptive cell transfer to optimise hematopoietic stem cell transplantation from HLA half-matched related donor in order to accelerate the reconstruction of the immune system.
· Coordination of a multicentre, randomised, prospective cohort clinical trial on the use of two different doses of a rabbit-derived anti-lymphocyte globulin to reduce GvHD in paediatric patients with malign blood diseases receiving an allogeneic hematopoietic stem cell transplant from donors with a different blood type.
Director: Dr. Alice Bertaina
Referring physician for the portal: Dr. Angela Mastronuzzi
Tel. (+39) 06-6859.2619
A parent or family member can assist hospitalised patients in a comfortable atmosphere; other family members can use a closed-circuit television and telephone to talk with children in isolation.